Literature DB >> 11229837

Risk factors for acquisition of levofloxacin-resistant Streptococcus pneumoniae: a case-control study.

P L Ho1, W S Tse, K W Tsang, T K Kwok, T K Ng, V C Cheng, R M Chan.   

Abstract

A case-control study was conducted to identify the risk factors associated with levofloxacin-resistant Streptococcus pneumoniae (LRSP) colonization or infection. Twenty-seven case patients (patients with LRSP) were compared with 54 controls (patients with levofloxacin-susceptible S. pneumoniae). Risk factors that were significantly associated with LRSP colonization or infection, according to univariate analysis, included an older age (median age, 75 years for case patients versus 72.5 years for controls), residence in a nursing home (odds ratio [OR], 7.2), history of recent (OR, 4.6) and multiple (OR, 4.4) hospitalizations, prior exposure to fluoroquinolones (OR, 10.6) and beta-lactams (OR, 8.6), presence of chronic obstructive pulmonary disease (COPD; OR, 5.9), and nosocomial origin of the bacteria (OR, 5.7). Multivariate analysis showed that presence of COPD (OR, 10.3), nosocomial origin of the bacteria (OR, 16.2), residence in a nursing home (OR, 7.4), and exposure to fluoroquinolones (OR, 10.7) were independently associated with LRSP colonization or infection. Thus, a distinct group of patients with COPD is the reservoir of LRSP.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11229837     DOI: 10.1086/319222

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  43 in total

1.  Trends in ciprofloxacin nonsusceptibility and levofloxacin resistance among Streptococcus pneumoniae isolates in North America.

Authors:  J A Karlowsky; L Nealy; D F Sahm; C Thornsberry; M E Jones
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

2.  Moxifloxacin for community-acquired pneumonia.

Authors:  Bart J A Rijnders
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Detection of resistance to gatifloxacin and moxifloxacin in Streptococcus pneumoniae with the VITEK 2 instrument.

Authors:  J H Jorgensen; S A Crawford; L M McElmeel; C G Whitney
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

4.  Upgrading antibiotic use within a class: tradeoff between resistance and treatment success.

Authors:  Y Claire Wang; Marc Lipsitch
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-13       Impact factor: 11.205

5.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

6.  Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.

Authors:  M de Cueto; J M Rodríguez; M J Soriano; L López-Cerero; J Venero; A Pascual
Journal:  J Clin Microbiol       Date:  2008-02-20       Impact factor: 5.948

Review 7.  Drug-resistant pneumococcal pneumonia: clinical relevance and approach to management.

Authors:  J D Fuller; A McGeer; D E Low
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2005-12       Impact factor: 3.267

8.  Genetic diversity of fluoroquinolone-nonsusceptible Streptococcus pneumoniae clinical isolates and the first identification of serotype 20B in China.

Authors:  Q Guo; C Zhuo; Y Xu; W Huang; C Wang; S Zhang; J Huang; F Hu; D Zhu; F Yang; M Wang
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-10-04       Impact factor: 3.267

Review 9.  Clinical role of beta-lactam/beta-lactamase inhibitor combinations.

Authors:  Nelson Lee; Kwok-Yung Yuen; Cyrus R Kumana
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 10.  Maintaining fluoroquinolone class efficacy: review of influencing factors.

Authors:  W Michael Scheld
Journal:  Emerg Infect Dis       Date:  2003-01       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.